Nuvectis Pharma is a biotechnology business based in the US. Nuvectis Pharma shares (NVCT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.87 – an increase of 6.68% over the previous week. Nuvectis Pharma employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $8.87 |
|---|---|
| 52-week range | $4.44 - $11.80 |
| 50-day moving average | $8.10 |
| 200-day moving average | $6.81 |
| Wall St. target price | $18.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.11 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.865 from 2025-04-17
| 1 week (2025-04-11) | 6.68% |
|---|---|
| 1 month (2025-03-20) | -5.19% |
| 3 months (2025-01-17) | 61.48% |
| 6 months (2024-10-18) | 16.64% |
| 1 year (2024-04-19) | 29.99% |
|---|---|
| 2 years (2023-04-19) | -39.41% |
| 3 years (2022-04-19) | 9.58 |
| 5 years (2020-04-16) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -65.65% |
| Return on equity TTM | -173.41% |
| Profit margin | 0% |
| Book value | $0.50 |
| Market Capitalization | $207.4 million |
TTM: trailing 12 months
We're not expecting Nuvectis Pharma to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Nuvectis Pharma's shares have ranged in value from as little as $4.44 up to $11.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nuvectis Pharma's is -0.12. This would suggest that Nuvectis Pharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Nuvectis Pharma has bucked the trend.
To put Nuvectis Pharma's beta into context you can compare it against those of similar companies.
Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.